Endoluminal Spasmolysis

PreclinicalSmall molecule

Endoluminal Spasmolysis is one of 28 small molecule programs targeting Cerebral Infarction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral InfarctionActive, not recruiting

Cerebral InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Cerebral Infarction

#DrugCompanyPhaseTrials

Lorelco

Sanofi

Approved

1 2

Plavix

Sanofi

Approved

1 3

Prevacid

Takeda

Approved

—4

Nimotop

AAzurity Pharmaceuticals

Approved

1 5

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Bayer Aspirin

2 7

Activase

Roche

Phase 3

—8

Neo-Synephrine

EExela Pharma Sciences, LLC.

Phase 3

1 9

Pletal

Otsuka

Phase 3

1 10

Xe-133

NNobilis Therapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Recruiting

Cerebral Infarction

NCT07305922

Clinical

Trials by Indication[1]

Cerebral Infarction1 trial

Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension

Recruiting·RRegion Stockholm··NCT07305922·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Endoluminal Spasmolysis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Endoluminal Spasmolysis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Endoluminal Spasmolysis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Stockholm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRegion Stockholm

Endoluminal Spasmolysis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Cerebral Infarction1 trial

References

Drug Info

Quick Facts

Related News